Paclical micellular paclitaxel: Phase III data

An open-label, European Phase III trial in 789 patients with epithelial ovarian cancer showed that 250 mg/m 2 Paclical given as a 1-hour infusion plus carboplatin on day 1 of each 21-day cycle met the primary endpoint of non-inferiority to paclitaxel plus carboplatin in improving PFS (10.3 vs. 10.1 months). The trial enrolled patients with recurrent epithelial cancer, primary peritoneal cancer or fallopian tube cancer. In 2011, Oasmia reported interim data from 400 patients in the trial (see BioCentury, Aug. 8, 2011 & Oct. 10, 2011). ...